IPCA Labs in pink of health after strong Q3 dose

IPCA Laboratories rose 1.2% to Rs 1262.9 after the company announced decent Q3 earnings during market hours today, 12 February 2020.

On a consolidated basis, IPCA Laboratories' net profit jumped 24.13% to Rs 197.61 crore in Q3 December 2019 as against 159.19 crore posted in Q3 December 2018. Revenue from operations rose 21% year-on-year (YoY) to Rs 1212.86 crore in Q3 December 2019.

Profit before tax (PBT) during the quarter stood at Rs 234.43 crore, up by 19.28% from Rs 196.53 crore reported in Q3 December 2018. Tax expense declined 1% year-on-year (YoY) to Rs 36.89 crore in Q3 December 2019.

 

EBITDA (before forex) jumped 37% to Rs 290.03 crore in Q3 December 2019 as compared to Rs 211.26 crore posted in Q3 December 2018. EBITDA margin grew to 23.56% in Q3 December 2019 from 20.72% recorded in Q3 December 2018.

Indian formulations income stood at Rs 485.63 crore, rising 15% YoY. Exports income surged 25% YoY to Rs 585.61 crore in Q3 December 2019.

The company has declared a dividend of Rs 5 per equity share and set a record date on 20 February 2020.

IPCA Laboratories is a manufacturer and supplier of over 10 active pharmaceutical ingredients (APIs).

Powered by Capital Market - Live News